Back to Atlas
APotentially durableResearch-only / high verification need
CMP-0118
Investigational/discontinued oncology
RG7112
Senolytic / p53-MDM2
Context-dependent senolytic/oncology research positioning
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Small molecule
- Primary mechanism
- MDM2 inhibition and p53 activation
- Primary market use
- Senolytic / oncology research
Pharmacology
- Molecular weight (Da)
- 728.8
- Oral bioavailability
- Oral investigational
- Half-life
- ~20-50 h; variable
- Route tags
- Route-dependent / verify
- Evidence level
- Clinical/Preclinical
- Clinical status
- Investigational/discontinued oncology
- Value-for-money score
- 3 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Oncology-grade MDM2 inhibitor; human senolytic role not established